These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 29193819

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE.
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [Abstract] [Full Text] [Related]

  • 7. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ, Mariz HA, Andrade LE, Kayser C.
    Rev Bras Reumatol; 2014 Aug; 54(6):452-8. PubMed ID: 25458027
    [Abstract] [Full Text] [Related]

  • 8. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jiménez SA, White B, Seibold JR, Wigley FM, Scleroderma Clinical Trials Consortium.
    Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
    [Abstract] [Full Text] [Related]

  • 9. Long-Term Data on Efficacy and Safety of Selexipag for Digital Systemic Sclerosis Vasculopathy.
    Di Battista M, Della Rossa A, Mosca M.
    J Rheumatol; 2024 Sep 01; 51(9):899-903. PubMed ID: 38879188
    [Abstract] [Full Text] [Related]

  • 10. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR.
    J Rheumatol; 2009 Oct 01; 36(10):2264-8. PubMed ID: 19755613
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep 01; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Raynaud's phenomenon and its impact on activities in daily life during one year of follow-up in early systemic sclerosis.
    Sandqvist G, Wollmer P, Scheja A, Wildt M, Hesselstrand R.
    Scand J Rheumatol; 2018 May 01; 47(3):206-209. PubMed ID: 28803485
    [Abstract] [Full Text] [Related]

  • 16. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis.
    Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A.
    Cochrane Database Syst Rev; 2000 May 01; 1998(2):CD000954. PubMed ID: 10796396
    [Abstract] [Full Text] [Related]

  • 17. Effect of the dual endothelin receptor antagonist bosentan on Raynaud's phenomenon secondary to systemic sclerosis: a double-blind prospective, randomized, placebo-controlled pilot study.
    Nguyen VA, Eisendle K, Gruber I, Hugl B, Reider D, Reider N.
    Rheumatology (Oxford); 2010 Mar 01; 49(3):583-7. PubMed ID: 20040526
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preliminary Clinical and Laser Speckle Contrast Analysis Data on Selexipag Efficacy for the Treatment of Digital Vasculopathy in Systemic Sclerosis.
    Di Battista M, Della Rossa A, Da Rio M, De Mattia G, Morganti R, Mosca M.
    J Rheumatol; 2023 Aug 01; 50(8):1029-1031. PubMed ID: 37003608
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Senet P, Maillard H, Diot E, Lazareth I, Blaise S, Arnault JP, Pistorius MA, Boulon C, Cogrel O, Warzocha U, Rivière S, Malloizel-Delaunay J, Servettaz A, Sassolas B, Viguier M, Monfort JB, Janique S, Vicaut E, BRASS collaborators.
    Arthritis Rheumatol; 2023 Mar 01; 75(3):459-467. PubMed ID: 36066501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.